Do peptides show up on a drug test? What each panel screens for

What a workplace drug test screens for

A federal workplace urine panel screens for ten analyte groups: marijuana, cocaine, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, fentanyl, amphetamines, and MDMA. Every one of them is a small drug of abuse. No peptide, hormone or growth factor appears anywhere on that list.

The question almost always means one of two very different things, and the answer flips depending on which one you are asking. Start with the common case: the urine cup at a new job, a commercial driving physical, or a federally regulated workplace. That panel is not a general search for foreign molecules in your body. It is a fixed, published list of named analytes (the specific chemicals a laboratory is instructed to look for), and the list is short.

The Department of Health and Human Services publishes it. The authorized urine panel in force since 7 July 2025 screens for the marijuana metabolite, the cocaine metabolite benzoylecgonine, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, fentanyl and norfentanyl, amphetamine and methamphetamine, and MDMA and MDA [1]. Each has a numeric cutoff attached, from 1 nanogram per millilitre for fentanyl up to 2,000 for codeine and morphine [1]. That is the whole panel.

Nothing on it is a peptide. Nothing on it is a hormone, a growth factor, or anything your body makes on its own. The reason is not that peptides are undetectable, as the rest of this article shows in detail. The reason is that the panel exists to answer a specific question about impairment and drugs of abuse, and it was built by HHS with input from the Department of Transportation, the FDA, the Department of Defense and the DEA to answer that question and no other [1]. A test that never looks for something will never find it, no matter how much of it is present.

Where peptides actually are tested

Anti-doping is the system that tests for peptides. The World Anti-Doping Agency publishes a Prohibited List that names growth hormone releasing peptides, GHRH analogues, growth hormone secretagogues, thymosin beta-4, IGF-1 and BPC-157 outright, and catches almost everything else through a category defined by regulatory status.

The other system is sport. The World Anti-Doping Agency (WADA) publishes an annual Prohibited List, an International Standard that took effect on 1 January 2026 in its current form, and peptides are all over it [2].

Section S2, "peptide hormones, growth factors, related substances, and mimetics", is prohibited at all times, meaning in and out of competition [2]. It names the growth hormone releasing hormone analogues CJC-1293, CJC-1295, sermorelin and tesamorelin; the growth hormone secretagogues anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin; and the growth hormone releasing peptides GHRP-1 through GHRP-6, hexarelin and alexamorelin [2]. Section S2.3 covers growth factors and adds IGF-1, the mechano growth factors, and thymosin beta-4 and its derivatives, TB-500 by name [2]. MOTS-c sits somewhere else entirely, in S4.4.1, as an activator of AMP-activated protein kinase [2].

The category that matters most for research peptides is S0, "non-approved substances". Its definition is deliberately open: any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use is prohibited at all times [2]. That wording catches a compound because of its regulatory status, not because anyone wrote its name down. BPC-157 is named there anyway, as an example rather than a limit [2].

Putting the two documents side by side is instructive, but not in the way you might expect. The overlap is large, not small: nine of the workplace panel's ten analyte groups contain something the 2026 List also prohibits, from cocaine and the amphetamines in S6 to fentanyl, morphine, hydromorphone, oxycodone and oxymorphone in S7 and cannabis in S8 [2][1]. Only phencyclidine has no counterpart [2]. What separates the two systems is therefore not the drugs of abuse but when the ban applies and what else it covers: every one of those overlapping classes is prohibited in-competition only, while S0, S2 and the metabolic modulators that hold the peptides are prohibited at all times [2]. No peptide is on the workplace panel at any hour of any day [1]. It is also worth saying what is absent from the 2026 List: semaglutide, tirzepatide, liraglutide and the rest of the GLP-1 class do not appear in it at all [2].

How long peptides stay detectable

Published excretion studies put most growth hormone releasing peptide detection windows inside two days. A single 10 mg oral dose of GHRP-2 left a detectable metabolite for over 20 hours. A nasal study found GHRP-2 markers at 47 hours and GHRP-6 metabolites at only 12, from one volunteer each.

This is where recall does the most damage, because the real numbers are published and they are specific. In the published work on these compounds, the laboratory is frequently not looking for the peptide someone injected at all: in one excretion study the intact drug was never observed while its metabolite was [6]. What gets targeted instead is the metabolites (the smaller fragments your body cuts it into), which is why a study of their metabolism describes itself as generating urinary metabolites potentially useful for routine doping controls [8].

The method paper that put GHRPs into routine screening validated extraction of GHRP-1, GHRP-2, GHRP-4, GHRP-5, GHRP-6, alexamorelin, ipamorelin and hexarelin from human urine, with limits of detection between 0.2 and 1 nanogram per millilitre and recovery from 47 to 95 percent [6]. Its proof of principle came from a single oral administration of 10 mg of GHRP-2, and the result is the one worth remembering: the known metabolite was detectable for over 20 hours, while the intact drug was never observed at all [6]. A separate study identified 28 metabolites across the GHRP family, at least three for each compound, though that work combined in vitro human models with in vivo administration in rats rather than people [8].

The closest thing to a real excretion curve comes from a nasal administration study that dosed one volunteer per compound and collected urine for two days [7]. GHRP-1 was never detected in its parent form, but a fragment of it was still there at 27 hours [7]. GHRP-2 and two of its metabolites were detectable at 47 hours, the longest window in the study [7]. GHRP-6 was mostly excreted unchanged and found at 23 hours, while its metabolites lasted only 12 [7]. The authors' own conclusion is the honest headline: the detection window depends on individual metabolism, the preparation and the route of administration [7]. With one volunteer per arm, these are illustrations of a range, not a schedule anyone can plan around.

Growth hormone breaks the clears-fast rule

Growth hormone is tested two ways, and neither behaves like the peptide tests. The isoform test detects low doses but only in a window of roughly 12 to 24 hours. The biomarker test measures what growth hormone did to your body, and in principle looks back one to two weeks.

Growth hormone itself is the exception that ruins any simple rule about clearance, and the reason is that detecting it is genuinely hard. Injected growth hormone is nearly identical to the growth hormone you already make, it has a short half-life, your own secretion fluctuates, and very little of it ends up in urine [3].

So the field built two tests. The isoform test exploits the fact that the recombinant drug is a single pure form while your own growth hormone circulates as a mixture of several. It works, but its main limitation is a window of roughly 12 to 24 hours after the last dose [3]. The second is the biomarker test, which ignores the hormone entirely and measures two things growth hormone drives up: IGF-1 and a fragment of collagen synthesis called P-III-NP. WADA accepted it in 2012, and it was arguably the first time a biomarker method was used for forensic purposes [4]. Its advertised window is one to two weeks [3].

What happens when someone tests both against real dosing is more interesting than either claim. Nine healthy men took low-dose recombinant growth hormone, 1 and 4 international units per day, for two weeks [5]. The isoform test flagged 80 percent of them as atypical, but only in the 1.5 to 3 hours directly after an injection [5]. Using the standard population-based decision limit, the biomarker score caught exactly one of the nine [5]. Only when IGF-1 and P-III-NP were tracked against each man's own baseline did the hit rate reach 88 percent [5]. A review of the biomarker method reaches the same verdict from the other direction: the promised long-term detection time has not been realised in practice, partly because the decision limits were set too high [4].

BPC-157 is the case study

BPC-157 is the clearest example of a research peptide that acquired a test. WADA added it to the Prohibited List in 2022 and still names it in 2026. A validated urine method now detects it and five metabolites down to 0.01 nanograms per millilitre.

If one compound shows how fast the "nobody tests for research peptides" position goes stale, it is BPC-157. It is a fifteen-amino-acid sequence, GEPPPGKPADDAGLV, and no proper clinical trial in humans has yet been performed to substantiate its healing claims, which has not stopped athletes using it [9]. Having no approval from any health authority is precisely what puts a compound in S0, and WADA added BPC-157 to the Prohibited List in 2022 [9]. Four annual revisions later it is still named there in the 2026 List [2].

The analytical work followed. A 2023 study used a stable isotope labelling approach, feeding laboratory models a version of BPC-157 built from heavier carbon and nitrogen atoms so its fragments could be picked out of the chemical noise, and characterised one metabolite from a previously unknown pathway plus eight from the ordinary route of breaking the bonds between amino acids [9]. That metabolite discovery was done in two incubation models rather than in people, which is a real limit on what it says about human excretion.

What was validated in human urine is the detection method itself, and its numbers are the point. It covers BPC-157 and its five main metabolites with limits of detection between 0.01 and 0.11 nanograms per millilitre, linearity across 0.02 to 50 nanograms per millilitre, and recovery above 90 percent [9]. For scale, the earlier GHRP screen bottomed out between 0.2 and 1 nanogram per millilitre [6], so the newer method reaches concentrations one to two orders of magnitude lower. The gap between "unapproved research chemical" and "routinely detectable at trace concentrations" is now a matter of a laboratory choosing to run the method.

What this actually means for you

If you are tested at work, the published panel does not include peptides and that is a fact about the panel, not permission. If you compete under anti-doping rules, the S0 category catches unapproved peptides by definition, prohibition applies year round, and no result depends on whether the compound worked.

For most people asking this question, the honest answer is short: a standard workplace urine screen does not test for peptides, because peptides are not on the panel [1]. That is a statement about what the laboratory was instructed to measure. It is not a safety finding, it is not a legality finding, and it says nothing at all about whether a given compound is worth taking.

For anyone in tested sport, the picture inverts and the details matter. Three features of the system are worth internalising. First, both S0 and S2 are prohibited at all times, which the List defines as in and out of competition [2]. There is no off-season during which an out-of-competition sample stops counting [2]. Second, S0 is written to catch a substance by regulatory status rather than by name, so a peptide nobody has heard of is still covered the moment it turns out no health authority has approved it for human use [2]. Third, biomarker methods do not need the parent compound at all: they look for what it did to you [4].

The List does distinguish specified from non-Specified substances, and it is easy to read too much into that. S0 substances are all Specified while S2 substances are not, but the Code's own comment is explicit that specified substances should not be considered less important or less dangerous, only more likely to have been taken for some reason other than enhancing performance [2]. And the entire framework runs on strict liability, the principle that what is in the sample is what counts [4].

One last piece of perspective, from the review literature rather than from a vendor. The scientific evidence that growth hormone actually enhances athletic performance is weak, a point its author notes is not widely appreciated either in athletic circles or by the public [3]. A compound can be banned, detectable at trace levels, career-ending in a sample, and still not do what it is sold to do.